Log in or Sign up for Free to view tailored content for your specialty!
Myeloproliferative Neoplasms News
Is hospitalization within the final 30 days of life appropriate for patients with hematologic malignancies?
Click here to read the Cover Story, “Hem/oncs toe ‘line in the sand’ between quest for cure, overly aggressive end-of-life care’.”
Hem/oncs toe ‘line in the sand’ between quest for cure, overly aggressive end-of-life care
Patients with hematologic malignancies are significantly more likely than those with solid tumors to receive chemotherapy or spend time in the hospital during their final month of life.
Log in or Sign up for Free to view tailored content for your specialty!
Payment reform, ‘runaway growth’ of 340B top new Community Oncology Alliance president’s priorities
Jeff Vacirca, MD, FACP, CEO and managing director of clinical research at New York Cancer Specialists in Long Island, N.Y., has been elected president of Community Oncology Alliance for the 2017-2018 term.
Genetic profiling can identify appropriate conditioning regimens in myelodysplastic syndrome
Analysis of genetic mutations in patients with myelodysplastic syndrome at the time of hematopoietic stem cell transplantation may help predict outcomes and identify subgroups of patients who will derive the most benefit from particular conditioning regimens, according to a study in The New England Journal of Medicine.
Strict clinical trial eligibility criteria exclude patients most likely to benefit from cancer treatment
Clinical trials routinely use strict enrollment criteria that exclude patients who are most likely to benefit from the treatment under investigation, according to study results published in Leukemia.
Better physician–patient communication needed about costs of cancer care
Physicians’ willingness to communicate with patients about the cost of cancer care appeared associated with improved patient satisfaction and lower out-of-pocket expenses.
Five updates for World Cancer Day
World Cancer Day — which will be observed today — was founded by the Union for International Cancer Control to raise awareness of cancer, and to emphasize the importance of prevention, detection and treatment.
ASCO requests $34.1 billion in federal funding to continue pace of cancer research
“Robust” federal funding is needed to build on recent advances in cancer research, ASCO’s senior vice president and chief medical officer, Richard L. Schilsky, MD, FASCO, said during a news conference on Capitol Hill on Wednesday.
Immunotherapy again named ASCO’s ‘Cancer Advance of the Year’
For the second year in a row, ASCO has named immunotherapy as its cancer advance of the year, according to “Clinical Cancer Advances 2017: ASCO’s Annual Report on Progress Against Cancer.”
Patients with stage IV cancer fare poorly after surgery
Patients who underwent surgery for stage IV cancer experienced high rates of hospital readmissions, referrals to extended care facilities, morbidity and mortality, according to study results published in PLOS One.